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CD45 (T200, leukocytecommon antigen) is a major cell membrane glycoprotein
expressed on all hematopoietic cells, except mature erythrocytes. The antigen has
been characterized in mouse, rat, human, and chicken and has similar properties
in all species (1-5) . Structural variants of CD45 that are selectively expressed on
specific classes oflymphocytes have been detected by both biochemical and immuno-
logical methods . At least four forms of CD45, ranging in size fromMr 180,000 to
220,000, can be resolved by SDS-PAGE, and anti-CD45 mAbs have been obtained
that discriminate between the differentM r species. Such restricted CD45 (CD45R)
mAbs have proved useful in identifying subpopulations of functional cells that dis-
play particular forms ofCD45 . In the rat, mAb OX-22 reacts with the 220,000Mr
speciesofCD45 on Bcellsand also asubfraction ofthe 190,000, 200,000, and 220,000
Mr species of CD45 from peripheral T cells . This mAb divides rat CD4 + T cells
into an OX-22+ subset that mediates graft-vs.-host activity and an OX-22 - subset
that provides B cell help in vitroandin vivo (reviewed in reference 6) . In the human,
two anti-CD45R mAbs, 2114 and UCHL-1, have been identified that reciprocally
split CD4+ T cells into two distinct subpopulations ; 2114+ cells when activated, can
induce suppression (7), whereas UCHL-1+ cells provide B cell help (8) . mAbs 2114
andUCHL-1 selectively react with the 220,000 and 200,000Mr species (9) and the
180,000M r species ofCD45, respectively (10) . In the mouse, mAbs have been de-
scribed that recognize a 220,000Mr form of CD45 referred to as B220 and react
either with only the B cell lineage or with B cells and a subpopulation of T cells
(11) . These antibodies have been used to identify cells of the B lineage, including
pre-B cells in the bone marrow.
Recent studies of the molecular genetics of CD45 and the determination of the
predicted primary structures of the polypeptides encoded by CD45 cDNAs from
a variety of lymphoid tissues and cell lines in the rat (3), mouse (1, 2), andhuman
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(4, 12) have shown that the protein heterogeneity of the antigen is due to the variable
expression of 3 alternatively spliced exons (A, B, and C) proximal to the 5' end of
the gene. Each exon encodes sequences of -50 amino acids that are differentially
expressed to generate at least five forms of CD45 (1-4, 12). These data have estab-
lished the molecular basis of the structural heterogeneity of CD45 and provide the
opportunity to more precisely define the antigenic specificities of mAbs that recog-
nize different forms of CD45 . mAb OX-22 recognizes an antigenic determinant dis-
played by two tryptic peptides of rat CD45 derived from a region proximal to the
NH2 terminus of the molecule. Although the NH2-terminal sequences of both pep-
tides are encoded by exon B, both peptides are sufficiently large to allow the possi-
bility that the OX-22 antigenic determinant is dependent upon the expression of
exon C (3). In the human, it has been shown that exon A is required for expression
of the 2H4 epitope (13).
In this report, we have prepared four cell lines that express each of the individual
forms of recombinant mouse CD45 that have been presently identified in the mouse
(1, 2), and we have used them to determine which alternatively spliced exons are
required to generate the antigenic determinants recognized by three widely used
CD45R mAbs, RA3-6132, RA3-2C2 (11), and 14.8 (14). In addition, another
anti-mouse CD45R mAb, C363 .16A, has been characterized that has a novel re-
stricted specificity.
Materials and Methods
mAbs.
￿
RA3-6132, RA3-2C2, and TIB122 (Ml/9.3.4.HL.2) were obtained from the Amer-
ican Type Culture Collection, Rockville, MD, and have been characterized previously (11).
mAb 14.8 was a gift from Dr. P. Kincade (Oklahoma Medical Research Foundation) (14).
mAb C363.16A, an IgG2a, is produced by a hybridoma derived from. rat spleen cells im-
munized with a cloned mouse Th line (Bottomly, K., M . Lugman, L. Greenbaum, S. Carding,
J. West, T. Pasqualini, and D. B. Murphy, manuscript submitted for publication). 13/2 is
an anti-CD45 mAb and has been characterized previously (15).
cDNA and Retroviral Constructs.
￿
A full-length mouse CD45 cDNA containing all three al-
ternatively spliced exons was constructed from a pUC9 subdone ofan Eco RI fragment span-
ning the 5' coding region derived from XmLC1 and a similarly subcloned Eco RI fragment
from XmLC2 that includes the remaining 3' coding sequence (1). Cla 1 linkers were added
at the 5' Nhe 1 site of the first fragment and Xho 1 linkers were added at the 3' Cla 1 site
of the second (see Fig. 1). The Cla 1/Eco RI and Eco Rl/Xho 1 fragments were ligated into
pAT153/Pvu II/8 modified by the introduction of an Xho 1 site to yield a full-length CD45
construct lacking a poly A addition site. This Cla 1/Xho 1 fragment was blunt end ligated
into the Xba 1 cloning site of pARVI (16). Inserts in the correct orientation were identified
by restriction enzyme analysis.
Another form containing alternative exons B and C was obtained from clone B15 kindly
provided by Y. Saga (Sloan-Kettering Institute for Cancer Research, New York) (2). A full-
length construct was made by the ligation of the B15 cDNA to an Eco RV/Eco RI fragment
and then an Eco Rl/Xho 1 fragment of the mouse CD45 cDNA (Fig. 1). This CD45 con-
struct was subcloned into a modified pUC18 vector and subsequently excised from the plasmid
using Sal 1 and Xho 1 enzymes.
The other two forms (expressing exon C or no alternative exons) were derived by oligonu-
cleotide site-directed mutagenesis from a 5' 2.2-kb Eco Rl/Sma 1 fragment of the 3 exon
form of CD45 subcloned into M13mp19 using 2 oligomers (24 and 25 mers). This generated
the precise deletions ofexons A and B and exons A, B, and C, respectively, which were verified
by sequencing and then the fragment was subcloned back into the original vector.
Transfection and Infection.
￿
PA12 cells were transiently transfected with each retroviral con-
struct, and after 48 h, the culture supernatant was used to infect $2 cells. These cells wereJOHNSON ET AL.
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then selected in 350 lAg/ml of active G418 and individual colonies were isolated and subse-
quently analyzed.
Flow Cytometry.
￿
Analysis ofCD45 expression was performedusingtheSalkInstitute flow
cytometer, essentiallyasdescribed in reference 17. Undiluted tissue culture supernatants (100
j1)containing mAbs 13/2, RA3.6B2, RA3.2C2, or C363.16A or a saturating dilution ofas-
cites containing mAb 14.8 were used as the primary reagents to stain 106 cells. Then, 50
tl ofFITC-labeled goat anti-rat IgG (Organon Teknica-Cappel, Malvern, PA) was used as
the second antibody at a dilution of 1:20.
Results and Discussion
The objective ofthese studies was to map the antigenic determinants recognized
by anti-CD45R mAbs more precisely by determiningtheir reactivity with celllines
expressing individual forms ofrecombinant mouse CD45. Three anti-13220 mAbs,
RA3-6B2, RA3-2C2, and 14.8, were chosen for study becauseoftheir extensiveprior
use to distinguish lymphocyte subpopulations. RA3-6132 appears to be specific for
CD45 on B cells, whereas RA3-2C2 and 14.8 recognize a form present on B cells
and at lower levels on CD8' T cells (18, 19). A fourth antibody, C363.16A, reacts
with the 190,000 and 220,000 Mr forms, but not the 180,000 Mr form ofCD45 and
appears to differentiate between two subpopulations of CD4' T cells (20).
To obtain cell lines expressing individual forms ofmouse CD45, four full-length
CD45 cDNAs were constructed as described in Materials and Methods, each en-
coding a single form ofCD45 glycoproteincontaining different combinations ofvari-
able exons A, B, and C. The cDNAs were then ligated into the retroviral vector
pARV1 (Fig. 1). These retroviral constructs were transiently transfected into PA12
cells and thesupernatants were used to infect *2 cells. Infected *2 cellswere selected
by their resistance toG418, and individual colonies were isolated and then analyzed
by flow cytometry for the expression ofmouse CD45 using the mAb 13/2. Cloned
cells expressing the highest amountsofCD45 ontheir cell surface were subsequently
used for the analysis of the binding specificities ofthe CD45R mAbs. The results
of these binding studies are shown in Fig. 2. mAbs RA3-2C2 and 14.8 had similar
patterns of reactivity, staining only *2 cells expressing the largest form of CD45
with sequences encoded by exons A, B, and C. As the antibodies do not react with
the CD45 glycoprotein containing the regions encoded by exons B and C, we can
conclude that both these mAbs recognize antigenic determinants that are depen-
dent upon the expression of exon A. In this respect, the mAbs are similar to the
2H4 mAb in the human. However, in contrast to 2H4, which splits the CD4'T cell
subset in thehuman (9), neither RA3-2C2 nor the 14.8 antibody has been reported
to react with CD4'T cells in the mouse. This may either reflect a species differ-
ence in the splicing out of exon A in CD4'T cells or a difference in the ability of
the mAbs to detect their respective antigens.
mAb C363.16A binds only to the forms ofCD45 encoded by cDNA constructs
containing exon B and, thus, clearly differs in specificity from RA3-2C2 and 14.8
mAbs. This antibody not only reacts with B cells and CD8'T cells but also splits
CD4' T cells (20). Although the most simple interpretation of the dependence of
antigenic determinants upon the expression ofa specific alternatively spliced exon
is that the exon encodes the polypeptide region to which the antigenic determinant
islocalized, it cannot be excluded on thebasis ofthe present data that other regions
of CD45 influence the antigenic site.1182
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FIGURE 1 .
￿
Structures of four
mouse CD45 constructs that
were ligated into the retroviral
expression vector, pARVI at the
Xba 1 site, between the splice
donor (SD) and splice acceptor
(SA) sites . The shaded region
represents the transmembrane
region (TM) and the stipled
boxes, the 5' and 3'untranslated
regions (UT). A, B, and Crep-
resent the three alternatively
spliced exons and the second
construct (expressing exons B
andC) has an alternative 5' un-
translated region derived from
clone B15 (2) . E, N, R, S, and
CrepresentEcoRI, Nco 1, Eco
RV, Sma 1, and Cla 1 restric-
tion sites, respectively . The un-
marked shaded region inpARV
1 represents pUC9 sequence
conferring Amp' .
RA3-6B2 does not bind to any of the four constructs expressed in *2 cells . One
explanation of this result could be that the determinant is dependent upon the ex-
pression ofacombination of alternatively spliced exons not represented by the four
constructs that were tested . Another is that the antigenic determinant requires a
post-translational modification ofthe CD45 antigen, such as theaddition of specific
oligosaccharide moieties that do not occur correctly in *2 cells. Expression of
sufficiently high levels of specific forms ofCD45 in mutant CD45- lymphoid cells
has not been obtained usingthe presentretroviral construct to directly test this latter
hypothesis . However, preliminary data suggests that neither neuraminidase diges-
tion normild periodate treatment affects the RA3-6B2 determinant . The antigenic
determinants of two widely used B220 antibodies have now been defined and the
expression of two of the three alternatively spliced exons can now be monitored by
specific antibodies . It should now be possible to establish in which lymphoid cells
and at what stages ofdevelopment these alternative exons are expressed, which may
provide insight into their functional significance .JOHNSON ET AL .
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FIGURE 2 .
￿
Analysis of anti-CD45 antibodies binding to *2 cells expressing different forms of
the molecule . Four *2 cell lines were assayed by indirect immunofluorescence usingmAbs 13/2,
RA3-6B2, RA3-2C2, 14.8, C363 .16A, and a negative control, tissue culture medium alone . A,
B, andCrepresent the variable exons that were expressed andT200/0 represents the construct
lacking the alternatively spliced exons. The x-axis represents fluorescence intensity on a loga-
rithmic scale and the vertical scale is cell number. The mean fluorescence is given in each histo-
gram andthenumber relates to the intensity offluorescence over the negative control . Theweak
labeling of the *2/T200/C cell line with the RA3-6B2 antibody seen in this particular experi-
ment was not reproducible.
Summary
Cell lines expressing specific variants ofmurine CD45 (T200) were established
by infection with retroviral constructs of four cDNAs encoding different forms of
CD45 . These lines were then used to determine which sequences encoded by alter-
natively spliced exons of CD45 were required to generate antigenic determinants
recognized by anti-CD45 mAbs . The binding oftwoB220 antibodies (14.8 and RA3-
2C2) to CD45 was dependent on theexpression ofthe first alternatively splicedexon
(exon A) . A third B220 antibody, RA3-6B2, did not bind to any of the forms of
CD45 expressed on fibroblasts . A newly defined anti-CD45R antibody, C363.16A,
reacts with an antigenic site dependent upon the expression of the second alterna-
tively spliced exon, exon B.
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